CJC-1295 in Dagotière — GHRH Analog Research Guide
CJC-1295 research guide for Dagotière. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers seeking out CJC-1295 in Dagotière rapidly learn that local retail options are nearly impossible to find. The key implication for Dagotière researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the quality verification approach is universal across all locations. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. The sections below cover what Dagotière researchers need to know about purchasing, testing, and working with CJC-1295 for research purposes.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Dagotière researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade CJC-1295
Before evaluating any specific vendor, understand what genuine quality documentation contains — so you can identify whether a supplier meets the standard. A COA for CJC-1295 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. Red flags in CJC-1295 vendor evaluation: prices significantly below market average, no information about manufacturing source, no community presence, and COAs that lack endotoxin data. Hold lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and return unused portion to the freezer.
Order CJC-1295 — ships to Dagotière
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and small-scale human observations. Proper handling of CJC-1295 requires sterile reconstitution technique — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and consistent cold chain handling. The primary quality-related safety risk in CJC-1295 research is bacterial endotoxin from low-quality material — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. Protocol documentation — documenting product details, dates, and administration precisely — is a research best practice for CJC-1295 that makes anomalous results interpretable.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
